Protective Effects of Infliximab Against Kanamycin-Induced Ototoxicity in Rats

Otol Neurotol. 2023 Aug 1;44(7):e463-e470. doi: 10.1097/MAO.0000000000003923. Epub 2023 Jun 15.

Abstract

Hypothesis: To examine the protective effects of infliximab (INF) against kanamycin (KM)-induced hearing loss.

Background: Tumor necrosis factor α blockers can reduce cellular inflammatory reactions and decrease cell death.

Methods: Thirty-six rats with normal hearing were randomly divided into six groups. The first group was injected with 400 mg/kg KM intramuscularly (IM), the second group with 7 mg/kg INF intraperitoneally (IP) and 400 mg/kg KM IM, the third group with 7 mg/kg INF IP and 200 mg/kg KM IM, and the fourth group with 1 mg/kg 6-methylprednisolone (MP) IP and 400 mg/kg KM IM. Group 5 was injected with 1 mg/kg MP IP and 200 mg/kg KM IM, and group 6 with saline IP once. Auditory brain-stem response (ABR) for hearing thresholds was performed on days 7 and 14. From the frozen sections of the cochlea, the area of the stria vascularis, the number of neurons in the spiral ganglion, the fluorescence intensity of hair cells (FIHC), postsynaptic density (PSD), and presynaptic ribbons (PSRs) were calculated.

Results: The KM-induced increase in hearing thresholds was detected on the 14th day. Hearing was only preserved in the group treated with INF after low-dose KM exposure but not in the groups that received high-dose KM. The FIHC, excitatory PSD, and PSR were preserved only in the INF-treated group after half-dose KM exposure. In MP groups, FIHC, excitatory PSD, and PSR were significantly lower than in the control group.

Conclusions: Our results support that tumor necrosis factor-based inflammation may play a role in the ototoxicity mechanism.

MeSH terms

  • Animals
  • Cochlea / pathology
  • Evoked Potentials, Auditory, Brain Stem
  • Infliximab / pharmacology
  • Infliximab / therapeutic use
  • Kanamycin* / toxicity
  • Ototoxicity* / etiology
  • Ototoxicity* / prevention & control
  • Rats
  • Stria Vascularis / pathology

Substances

  • Kanamycin
  • Infliximab